(S)-benzyl (1-oxobutan-2-yl)carbamate | 143915-15-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-benzyl (1-oxobutan-2-yl)carbamate
• 英文别名: benzyl (S)-(1-oxobutan-2-yl)carbamate；(S)-N-Cbz-ethylglycinal；(S)-1-oxobutane-2-benzylcarbamate；Cbz-ethylglycinal；(S)-2-(N-Benzyloxycarbonylamino)-butyraldehyde；benzyl [(1S)-1-formylpropyl]carbamate；Cbz-(L)-α-ethylglycinal；benzyl N-[(2S)-1-oxobutan-2-yl]carbamate
• CAS: 143915-15-5
• 化学式: C₁₂H₁₅NO₃
• 分子量: 221.256
• InChiKey: FHBZMZYIIZXDGB-NSHDSACASA-N

物化性质

• 沸点：
  360.0±35.0 °C(Predicted)
• 密度：
  1.115±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-benzyl (1-oxobutan-2-yl)carbamate 在 碘 、 silver trifluoromethanesulfonate 、 碳酸氢钠 作用下， 以 四氯化碳 、 二氯甲烷 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  Stereoselective silver triflate-mediated iodocyclization of carbamates

  摘要：

  Iodocyclization of carbamates involving electron-deficient olefins, (i.e. alpha,beta-unsaturated esters) is greatly facilitated by the use of silver(I) triflate and proceeds with excellent trans ring stereoselectivity. During this process, the resultant iodides can undergo epimerization, the rate of which is solvent-dependent.

  DOI：

  10.1016/s0040-4039(00)74232-8
• 作为产物：
  描述：

  (S)-methyl 2-(((benzyloxy)carbonyl)amino)butanoate 在 argon;bis(2-methylpropyl)alumane 、 Rochelle's salt 、 乙酸乙酯 、 Brine 、 Sodium sulfate-III 、 SiO2 作用下， 以 甲苯 为溶剂， 反应 1.33h， 以to give the title compound (1.18 g, 64%) as a colorless oil的产率得到(S)-benzyl (1-oxobutan-2-yl)carbamate
  参考文献：
  名称：

  Oxazolidin-2-one-Pyrimidine Derivatives

  摘要：

  本发明涉及以噁唑啉-2-酮取代的嘧啶化合物，其作为PI3K（磷脂酰肌醇-3-激酶）抑制剂，以及其药物组成物，其制造方法和用于治疗依赖于PI3K的疾病、病症和障碍的用途。

  公开号：

  US20140135330A1

文献信息

• Optically Active N- and C-Terminal Building Blocks for the Synthesis of Peptidyl Olefin Peptidomimetics
  作者：Sima Mirilashvili、Naama Chasid-Rubinstein、Amnon Albeck

  DOI：10.1002/ejoc.201000539

  日期：2010.8

  peptidomimetics serve as biologically active compounds or as intermediates for other peptidyl isosteres. The N-terminal side of the C=C bond could be easily prepared in an optically pure form from α-amino acids. Synthesis of C-terminal building blocks in an optically pure form is more challenging. We developed a chemoenzymatic stereoselective approach to such optically active C-terminal building blocks to

  肽基烯烃肽模拟物用作生物活性化合物或用作其他肽基等排体的中间体。C=C 键的 N 端侧可以很容易地从 α-氨基酸以光学纯的形式制备。以光学纯形式合成 C 端结构单元更具挑战性。我们开发了一种化学酶立体选择性方法，用于通过各种反应组装成肽基烯烃的光学活性 C 端结构单元。它们包括亲电子醛和亲核砜、鏻盐、膦酸盐和二硒化物。前手性二酯到相应羟基酯的关键酶水解引入了光学活性。随后化学反应的顺序，无论是保护-水解-功能化还是功能化-水解-保护，
• Antitumoral compounds
  申请人：——

  公开号：US20040048834A1

  公开（公告）日：2004-03-11

  New spisulosine derivatives of use in treating tumors are of the formula (I) wherein: each X is the same or different, and represents H, OH, OR′, SH, SR′, SOR′, SO 2 R′, NO 2 , NH 2 , NHR′, N(R′) 2 , CN, halogen, C(═O)H, C(═O)CH 3 , CO 2 H, CO 2 CH 3 , substituted or unsubstituted C 1 -C 18 alkyl, substituted or unsubstituted C 2 -C 18 alkenyl, substituted or unsubstituted C 2 -C 18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaromatic, or two groups X may together form ═O; Y is NR 1 , OR 1 , PR 1 , SR 1 , or halogen, wherein the number of substituents R 1 is selected to suit the valency and each R 1 is independently selected of H, OH, C(═O)R′, P(═O)R′R″, substituted or unsubstituted C 1 -C 18 alkyl, substituted or unsubstituted C 2 -C 18 alkenyl, substituted or unsubstituted C 2 -C 18 alkynyl, substituted or unsubstituted aryl, and wherein the dotted line indicates an optional double bond; each Z is the same different, and represents H, OH, OR′, SH, SR′, SOR′, SO 2 R′, NO 2 , NH 2 , NHR′, N(R′) 2 , NHC(O)R′, CN, halogen, C(═O)H, C(═O)CH 3 , CO 2 H, CO 2 CH 3 , substituted or unsubstituted C 1 -C 18 alkyl, substituted or unsubstituted C 2 -C 18 alkenyl, substituted or unsubstituted C 2 -C 18 alkenyl, substituted or unsubstituted C 2 -C 18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaromatic, or two groups Z may together form ═O; z is 0 to 25; y is to 0 to 20; R 2 is H, C(═O)R′, P(═O)R′R″, S(═O)R′R″, S(═O) 2 R′, substituted or unsubstituted C 1 -C 18 alkyl, substituted or unsubstituted C 2 -C 18 Alkenyl, substituted or unsubstituted C 2 -C 18 alkynyl, substituted or unsubstituted aryl; R 3 is H, C(═O)R′, P(═O)R′R″, S(═O)R′R″, S(═O) 2 R′, substituted or unsubstituted C 1 -C 18 alklyl, substituted or unsubstituted C 2 -C 18 alkenyl, substituted or unsubstituted C 2 -C 18 alkynyl, substituted or unsubstituted aryl; each of the R′, R″ groups is independently selected from the group consisting of H, OH, NO 2 , NH 2 , SH, CN, halogen, ═O, C(═O)H, C(═O)CH 3 , CO 2 H, CO 2 CH 3 , substituted or unsubstituted C 1 -C 18 alkyl, substituted or unsubstituted C 1 -C 18 alkoxy, substituted or unsubstituted C 2 -C 18 alkenyl, substituted or unsubstituted C 2 -C 18 alkynl, substituted or unsubstituted aryl; there may be one or more unsaturations in the hydrocarbon backbone defined by the chain (II) and salts thereof; with the exception of a C 16 -C 24 2-amino-3-hydroxyalkane or a C 16 -C 24 2-amino-3-hydroxyalkene.

  新的用于治疗肿瘤的斯皮苏林衍生物的化学式为（I），其中：每个X相同或不同，表示H、OH、OR′、SH、SR′、SOR′、SO2R′、NO2、NH2、NHR′、N(R′)2、CN、卤素、C(═O)H、C(═O)CH3、CO2H、CO2CH3、取代或未取代的C1-C18烷基、取代或未取代的C2-C18烯基、取代或未取代的C2-C18炔基、取代或未取代的芳基、取代或未取代的杂芳基，或两个X基团可能共同形成═O；Y为NR1、OR1、PR1、SR1或卤素，其中取代基R1的数量选择以适应化合价，每个R1独立选择自H、OH、C(═O)R′、P(═O)R′R″、取代或未取代的C1-C18烷基、取代或未取代的C2-C18烯基、取代或未取代的C2-C18炔基、取代或未取代的芳基，虚线表示可选的双键；每个Z相同或不同，表示H、OH、OR′、SH、SR′、SOR′、SO2R′、NO2、NH2、NHR′、N(R′)2、NHC(O)R′、CN、卤素、C(═O)H、C(═O)CH3、CO2H、CO2CH3、取代或未取代的C1-C18烷基、取代或未取代的C2-C18烯基、取代或未取代的C2-C18炔基、取代或未取代的芳基、取代或未取代的杂芳基，或两个Z基团可能共同形成═O；z为0至25；y为0至20；R2为H、C(═O)R′、P(═O)R′R″、S(═O)R′R″、S(═O)2R′、取代或未取代的C1-C18烷基、取代或未取代的C2-C18烯基、取代或未取代的C2-C18炔基、取代或未取代的芳基；R3为H、C(═O)R′、P(═O)R′R″、S(═O)R′R″、S(═O)2R′、取代或未取代的C1-C18烷基、取代或未取代的C2-C18烯基、取代或未取代的C2-C18炔基、取代或未取代的芳基；每个R′、R″基团独立选择自H、OH、NO2、NH2、SH、CN、卤素、═O、C(═O)H、C(═O)CH3、CO2H、CO2CH3、取代或未取代的C1-C18烷基、取代或未取代的C1-C18烷氧基、取代或未取代的C2-C18烯基、取代或未取代的C2-C18炔基、取代或未取代的芳基；碳链（II）中的碳氢骨架中可能存在一个或多个不饱和度，及其盐；除了C16-C242-氨基-3-羟基烷或C16-C242-氨基-3-羟基烯。
• Cyclic amine compounds
  申请人：Hasuoka Atsushi

  公开号：US20090042967A1

  公开（公告）日：2009-02-12

  The present invention relates to pharmaceutical agents which are agents for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; the pharmaceutical agents frailty suppressants, muscle strength enhancers, muscle increasing agents, cachexia suppressants, body weight decrease suppressants, agents for the prophylaxis or treatment of prostate hypertrophy, amyotrophy or muscle loss caused by a disease or an agent for reducing the prostate weight. The present invention also relates to methods for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis in a mammal, which comprises administering an effective amount of the pharmaceutical agents of the present invention or a prodrug thereof; use of the pharmaceutical agents of the present invention or a prodrug thereof for the production of an agent for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; and the like.

  本发明涉及用于预防或治疗性腺功能减退症、男性更年期障碍、虚弱、消瘦或骨质疏松症的药物剂，其中包括虚弱抑制剂、肌肉力量增强剂、肌肉增长剂、消瘦抑制剂、体重减少抑制剂、用于预防或治疗前列腺肥大、肌萎缩或疾病引起的肌肉流失或降低前列腺重量的药物剂。本发明还涉及一种在哺乳动物中预防或治疗性腺功能减退症、男性更年期障碍、虚弱、消瘦或骨质疏松症的方法，包括向其投予本发明的药物剂或其前药的有效量；使用本发明的药物剂或其前药生产用于预防或治疗性腺功能减退症、男性更年期障碍、虚弱、消瘦或骨质疏松症的药物剂；等等。
• Dihydroxyacetone Phosphate Aldolase Catalyzed Synthesis of Structurally Diverse Polyhydroxylated Pyrrolidine Derivatives and Evaluation of their Glycosidase Inhibitory Properties
  作者：Jordi Calveras、Meritxell Egido-Gabás、Livia Gómez、Josefina Casas、Teodor Parella、Jesús Joglar、Jordi Bujons、Pere Clapés

  DOI：10.1002/chem.200900838

  日期：2009.7.27

  The polyhydroxylated pyrrolidines generated were tested as inhibitors against seven glycosidases. Among them, good inhibitors of α‐L‐fucosidase (IC50=1–20 μM), moderate of α‐L‐rhamnosidase (IC50=7–150 μM), and weak of α‐D‐mannosidase (IC50=80–400 μM) were identified. The apparent inhibition constant values (Ki) were calculated for the most relevant inhibitors and computational docking studies were

  据报道，通过DHAP醛缩酶的催化，醛醇将磷酸二羟基丙酮磷酸酯（DHAP）加成到C-α-取代的N -Cbz-2-氨基醛衍生物上而生成的吡咯烷型亚氨基糖的化学酶法合成。来自大肠杆菌的L-藻糖-1-磷酸醛缩酶（FucA）和L-鼠李糖-1磷酸醛缩酶（RhuA）用作生物催化剂以在亚氨基糖上产生构型多样性。FucA催化剂可很好地耐受C-α处的烷基线性取代（即40-70％转化为醛醇加合物），而除二甲基和苄基取代（20％）外，未观察到具有C-α-烷基支链取代的产物。 。RhuA是用途最广泛的生物催化剂：C-α-烷基直链基团转化为羟醛加成物的转化率最高（60-99％），而C-α-烷基支链基团的转化率中等至良好（50-80％），二甲基和苄基取代基（20％）除外。FucA是最具立体选择性的生物催化剂（90％至100％的抗（3 R，4 R）加合物）。RhuA对（S）-N具有高度立体选择性-Cbz -2-氨基醛（90-100％顺式（即，3
• Highly efficient aldol additions of DHA and DHAP to N-Cbz-amino aldehydes catalyzed by l-rhamnulose-1-phosphate and l-fuculose-1-phosphate aldolases in aqueous borate buffer
  作者：Xavier Garrabou、Jordi Calveras、Jesús Joglar、Teodor Parella、Jordi Bujons、Pere Clapés

  DOI：10.1039/c1ob06263h

  日期：——

  Aldol addition reactions of dihydroxyacetone (DHA) to N-Cbz-amino aldehydes catalyzed by L-rhamnulose-1-phosphate aldolase (RhuA) in the presence of borate buffer are reported. High yields of aldol adduct (e.g. 70–90%) were achieved with excellent (>98 : 2 syn/anti) stereoselectivity for most S or R configured acceptors, which compares favorably to the reactions performed with DHAP. The stereochemical outcome was different and depended on the N-Cbz-amino aldehyde enantiomer: the S acceptors gave the syn (3R,4S) aldol adduct whereas the R ones gave the anti (3R,4R) diastereomer. Moreover, the tactical use of Cbz protecting group allows simple and efficient elimination of borate and excess of DHA by reverse phase column chromatography or even by simple extraction. This, in addition to the use of unphosphorylated donor nucleophile, makes a useful and expedient methodology for the synthesis of structurally diverse iminocyclitols. The performance of aldol additions of dihydroxyacetone phosphate (DHAP) to N-Cbz-amino aldehydes using RhuA and L-fuculose-1-phosphate aldolase (FucA) catalyst in borate buffer was also evaluated. For FucA catalysts, including FucA F131A, the initial velocity of the aldol addition reactions using DHAP were between 2 and 10 times faster and the yields between 1.5 and 4 times higher than those in triethanolamine buffer. In this case, the retroaldol velocities measured for some aldol adducts were lower than those without borate buffer indicating some trapping effect that could explain the improvement of yields.

  报告了二羟基丙酮（DHA）与N-Cbz-氨基醛的 aldol 加成反应，该反应是在硼酸盐缓冲液存在下，由 L-鼠李糖-1-磷酸 aldol 酶（RhuA）催化进行的。大部分 S或 R 配置的受体都可以以高产率（例如 70–90%）获得 aldol 加合物，并具有优异的立体选择性（>98 : 2 syn/anti），这与使用 DHAP 进行的反应相比表现良好。立体化学结果不同，依赖于 N-Cbz-氨基醛的对映异构体：S 受体产生 syn（3R,4S）aldol 加合物，而 R 受体则产生 anti（3R,4R）联体异构体。此外，策略性地使用 Cbz 保护基团使得通过反相色谱或简单提取可以简单高效地去除硼酸盐和多余的 DHA。这一点，加上使用未磷酸化的供体亲核试剂，使得合成结构多样性免疫环醇的方法更为实用和高效。同时，评估了使用 RhuA 和 L-岩藻糖-1-磷酸 aldol 酶（FucA）催化剂在硼酸盐缓冲液中对 N-Cbz-氨基醛进行二羟基丙酮磷酸盐（DHAP）进行的 aldol 加成反应的表现。对于 FucA 催化剂（包括 FucA F131A），使用 DHAP 的 aldol 加成反应的初始速率是三乙醇胺缓冲液中反应的 2 到 10 倍，产率高出 1.5 到 4 倍。在这种情况下，测得某些 aldol 加合物的逆 aldol 速率低于不含硼酸盐缓冲液的情况，这表明存在某种捕获效应，可以解释产率的提高。